olivLaw · US equity research
Zai Lab Limited ZLAB
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
Zai Lab is a biopharmaceutical company with a substantial presence in Greater China and the United States, commercializing products in oncology, immunology, neuroscience and infectious disease while developing its own candidates, including zoci. The company reported total revenue of 460.2 million USD in fiscal 2025, and 106.3 million USD in the second quarter of 2026 as it shifts toward a more developed internal portfolio.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 05 Nov 2026, Zai Lab Limited (ZLAB) stock was 22.60 USD (−0.88% on the day), with market capitalisation 2.0 bn USD, beta 0.93, 52-week range 16.30–27.00 USD. Latest reported quarter (Q3 2026): revenue of 108.2 m USD (−6.8% YoY), net income of -46.1 m USD, diluted EPS -0.04 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 44.6
- weak (30–45)
- Bollinger (20, 2)
- 21.25 – 25.32
- in the lower half of the band · %B 0.33 · band width 17.5%
- SMA 50 / 200
- 24.64 / 21.05
- mixed trend
- MACD (12, 26, 9)
- -0.65 / -0.57
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −11.6% | −5.9% | −5.7 pp | — |
| 3 months | +8.2% | −4.6% | +12.9 pp | — |
| 6 months | +14.3% | +0.2% | +14.1 pp | — |
| Year to date | +28.1% | +7.4% | +20.7 pp | — |
| 1 year | −8.9% | +8.2% | −17.1 pp | +15.1% |
| 3 years | −19.1% | +68.4% | −87.5 pp | +15.7% |
| 5 years | −74.5% | +56.5% | −131.0 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 109.1 m | 106.5 m | 110.0 m | 116.1 m | 127.6 m | 99.6 m | 106.3 m | 108.2 m |
| Cost of revenue | 41.8 m | 38.5 m | 43.0 m | 46.8 m | 62.3 m | 38.3 m | 48.2 m | 51.3 m |
| Research & development | 52.3 m | 60.7 m | 50.6 m | 47.9 m | 61.6 m | 65.6 m | 61.8 m | 49.8 m |
| SG&A | 82.6 m | 63.4 m | 71.0 m | 70.1 m | 73.0 m | 65.1 m | 72.9 m | 70.1 m |
| Operating income | -67.9 m | -56.3 m | -54.9 m | -48.8 m | -69.4 m | -69.4 m | -76.5 m | -63.0 m |
| Depreciation & amortisation | 3.0 m | 3.5 m | 3.7 m ≈ | 3.9 m ≈ | 3.9 m | 3.9 m | 4.2 m ≈ | 4.4 m ≈ |
| Interest expense | 904.0 k | 1.2 m | 1.3 m | 1.4 m | 1.4 m | 1.6 m | 1.6 m | 1.6 m |
| Pre-tax income | -81.7 m | -48.4 m | -40.7 m | -36.0 m | -53.3 m | -49.6 m | -51.8 m | -48.0 m |
| Income tax | 0 | 0 | 0 | 0 | -2.9 m | 1.4 m | -1.0 m | -1.9 m |
| Net income | -81.7 m | -48.4 m | -40.7 m | -36.0 m | -50.4 m | -51.0 m | -50.8 m | -46.1 m |
| Diluted EPS | -0.08 ≈ | -0.04 | -0.04 | -0.03 | -0.05 ≈ | -0.05 | -0.05 | -0.04 |
| Operating cash flow | -55.8 m | -61.7 m | -31.0 m ≈ | -32.0 m ≈ | -26.0 m | -11.9 m | -63.4 m ≈ | -57.9 m ≈ |
| Capex | 2.6 m | 1.5 m | 2.9 m ≈ | 3.0 m ≈ | 677.0 k | 1.2 m | 1.3 m ≈ | 947.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | ⚠ 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 129.0 k | 13.0 m | 49.0 m | 144.3 m | 215.0 m | 266.7 m | 399.0 m | 460.2 m |
| Revenue YoY | unavailable | — | +277.0% | +194.8% | +49.0% | +24.0% | +49.6% | +15.3% |
| Net income | -139.1 m | -195.1 m | -268.9 m | -704.5 m | -443.3 m | -334.6 m | -257.1 m | -175.5 m |
| Net income YoY | unavailable | — | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | -0.35 | -0.76 | -0.46 | -0.35 | -0.26 | -0.16 |
| Diluted EPS YoY | unavailable | — | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -107,810.1% | -1,502.3% | -549.3% | -488.2% | -206.1% | -125.5% | -64.4% | -38.1% |
| Free cash flow | -107.6 m | -197.0 m | -226.2 m | -567.5 m | -392.2 m | -205.4 m | -220.5 m | -158.9 m |
The series breaks before 2019: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 679.6 m USD
- Financial debt
- 204.5 m USD
- Net debt
- -475.0 m USD
- Equity
- 715.5 m USD
- Total assets
- 1.2 bn USD
- Debt / equity
- 0.29x
- Current ratio
- 2.45x
- ROE
- -22.6%
- ROA
- -14.9%
- FCF margin
- -34.5%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 49.0 m | 144.3 m | 215.0 m | 266.7 m | 399.0 m | 460.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Cost of revenue | 16.7 m | 52.2 m | 74.0 m | 95.8 m | 147.1 m | 190.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Gross profit | 32.2 m ≈ | 92.1 m ≈ | 141.0 m ≈ | 170.9 m ≈ | 251.9 m ≈ | 269.6 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Research & development | 222.7 m | 573.3 m | 286.4 m | 265.9 m | 234.5 m | 220.9 m | SEC (XBRL)· 26 Feb 2026verified |
| SG&A | 111.3 m | 218.8 m | 259.0 m | 281.6 m | 298.7 m | 277.6 m | SEC (XBRL)· 26 Feb 2026verified |
| Operating income | -301.8 m | -700.1 m | -404.4 m | -366.6 m | -282.1 m | -229.4 m | SEC (XBRL)· 26 Feb 2026verified |
| Depreciation & amortisation | 4.6 m | 6.5 m | 8.2 m | 9.0 m | 11.9 m | 15.0 m | SEC (XBRL)· 26 Feb 2026verified |
| EBITDA | -297.2 m ≈ | -693.6 m ≈ | -396.1 m ≈ | -357.5 m ≈ | -270.3 m ≈ | -214.4 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Interest expense | 181.0 k | 0 | 0 | 0 | 2.3 m | 5.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Pre-tax income | -268.9 m | -704.5 m | -443.3 m | -334.6 m | -257.1 m | -178.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Income tax | 0 | 0 | 0 | 0 | 0 | -2.9 m | SEC (XBRL)· 26 Feb 2026verified |
| Net income | -268.9 m | -704.5 m | -443.3 m | -334.6 m | -257.1 m | -175.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Diluted EPS | -0.35 | -0.76 | -0.46 | -0.35 | -0.26 | -0.16 | SEC (XBRL)· 26 Feb 2026verified |
| Weighted average diluted shares | 776.7 m | 929.9 m | 958.1 m | 966.4 m | 989.5 m | 1.1 bn | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 442.1 m | 964.1 m | 1.0 bn | 790.2 m | 449.7 m | 679.6 m | SEC (XBRL)· 26 Feb 2026verified |
| Receivables | 5.2 m | 47.5 m | 40.0 m | 59.2 m | 85.2 m | 106.1 m | SEC (XBRL)· 26 Feb 2026verified |
| Inventories | 13.1 m | 19.0 m | 31.6 m | 44.8 m | 39.9 m | 74.7 m | SEC (XBRL)· 26 Feb 2026verified |
| Current assets | 1.2 bn | 1.5 bn | 1.1 bn | 939.6 m | 1.1 bn | 1.0 bn | SEC (XBRL)· 26 Feb 2026verified |
| Property, plant & equipment, net | 29.2 m | 43.1 m | 57.9 m | 53.7 m | 48.0 m | 47.4 m | SEC (XBRL)· 26 Feb 2026verified |
| Intangibles (excl. goodwill) | 1.5 m | 1.8 m | 1.5 m | 13.4 m | 56.0 m | 76.1 m | SEC (XBRL)· 26 Feb 2026verified |
| Total assets | 1.3 bn | 1.6 bn | 1.2 bn | 1.0 bn | 1.2 bn | 1.2 bn | SEC (XBRL)· 26 Feb 2026verified |
| Accounts payable | 62.6 m | 126.2 m | 66.0 m | 113.0 m | 100.9 m | 141.6 m | SEC (XBRL)· 26 Feb 2026verified |
| Short-term debt | — | — | — | 0 | 131.7 m | 204.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Current liabilities | 98.0 m | 192.9 m | 139.8 m | 203.1 m | 299.4 m | 416.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Total liabilities | 128.3 m | 230.0 m | 174.5 m | 240.2 m | 344.9 m | 456.9 m | SEC (XBRL)· 26 Feb 2026verified |
| Equity | 1.2 bn † | 1.4 bn † | 1.0 bn † | 796.1 m † | 840.9 m † | 715.5 m † | SEC (XBRL)· 26 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -216.1 m | -549.2 m | -367.6 m | -198.2 m | -214.9 m | -150.8 m | SEC (XBRL)· 26 Feb 2026verified |
| Capex | 10.1 m | 18.3 m | 24.6 m | 7.2 m | 5.7 m | 8.1 m | SEC (XBRL)· 26 Feb 2026verified |
| Free cash flow | -226.2 m ≈ | -567.5 m ≈ | -392.2 m ≈ | -205.4 m ≈ | -220.5 m ≈ | -158.9 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Investing cash flow | -554.8 m | 250.0 m | 420.0 m | -10.8 m | -375.2 m | 307.9 m | SEC (XBRL)· 26 Feb 2026verified |
| Financing cash flow | 1.1 bn | 820.2 m | -1.7 m | -6.4 m | 349.9 m | 72.4 m | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 43.8% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 2.0 bn USD
Key indicators
Coverage and freshness
Score by group
44% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the base of the ratio is not positive
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 43.8% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -91.3% | 0 (vs peers) | 24% |
| Net margin · Quality | -44.9% | 23 (vs peers) | 14% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 28.9% | 100 (on a fixed band) | 19% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -45.2x | 0 (on a fixed band) | 14% |
| Current ratio · Balance sheet | 2.0x | 100 (on a fixed band) | 10% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -8.2% | 0 (on a fixed band) | 19% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality9/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
ZAI LAB LIMITED (ZLAB). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 460.2 m USD in 2025; YoY growth 15.3%; net margin -44.9%; ROE -30.0%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (score weight coverage: 43.8% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 28.9%
- Current ratio: 2.0x
What contradicts it
- ROIC: -91.3%
- Net margin: -44.9%
- Interest coverage: -45.2x
- FCF yield: -8.2%
Not assessed (insufficient data or a ratio without meaning): FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,283.9 bn | 44.3 | 86.1% | 31.9% | +44.7% | +27% / +131% |
| JNJJohnson & Johnson | 655.6 bn | 41.3 | 20.0% | 16.2% | +6.0% | +32% / +76% |
| ONCBeone Medicines Ltd. | 575.0 bn | 640.9 | 18.4% | 13.9% | +40.2% | +14% / +107% |
| ABBVAbbVie Inc. | 509.5 bn | 49.6 | — | 15.7% | +8.6% | +27% / +102% |
| MRKMerck & Co., Inc. | 362.2 bn | 151.2 | 5.1% | 3.6% | +1.3% | +40% / +43% |
| ABTAbbott Laboratories | 196.7 bn | 42.3 | 9.2% | 9.7% | +5.7% | −12% / +9% |
| PFEPfizer Inc | 170.3 bn | 42.6 | 4.4% | 6.3% | −1.6% | +16% / −2% |
| VRTXVertex Pharmaceuticals Inc | 137.5 bn | 34.9 | 20.8% | 30.7% | +8.9% | +25% / +53% |
| BMYBristol-Myers Squibb Company | 129.0 bn | 14.0 | 44.1% | 18.5% | −0.2% | +28% / +28% |
| TEVATeva Pharmaceutical Industries Limited | 48.8 bn | 97.3 | 6.6% | 3.6% | +4.3% | +55% / +325% |
| ZTSZoetis Inc. | 33.4 bn | 13.8 | 57.6% | 26.4% | +2.3% | −36% / −54% |
| ROIVRoivant Sciences Ltd. | 26.5 bn | — | -6.2% | -3,535.0% | −71.6% | +76% / +283% |
| RPRXRoyalty Pharma plc | 26.2 bn | 47.7 | 6.9% | 25.7% | +5.1% | +69% / +150% |
| UTHRUnited Therapeutics Corporation | 24.1 bn | 21.3 | 19.1% | 38.6% | +10.6% | +16% / +136% |
| INSMInsmed Inc | 23.9 bn | — | -72.5% | -39.9% | +66.7% | −48% / +335% |
| VTRSViatris Inc. | 21.7 bn | — | -24.3% | -23.9% | −3.0% | +77% / +107% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.0 bn | 7.9 | 126.6% | 52.8% | +65.2% | −65% / −7% |
| BBIOBridgeBio Pharma, Inc. | 14.5 bn | — | — | -61.3% | +126.3% | +3% / +159% |
| MDGLMadrigal Pharmaceuticals, Inc. | 9.3 bn | — | -24.8% | -10.9% | +432.1% | −33% / +97% |
| OGNOrganon & Co. | 3.6 bn | 18.0 | 20.3% | 3.5% | −2.9% | +79% / +22% |
| ZLABZai Lab Limited | 2.0 bn | — | -30.0% | -44.9% | +15.3% | −9% / −19% |
| SLSSELLAS Life Sciences Group, Inc. | 1.6 bn | — | -39.6% | — | −100.0% | +386% / +658% |
| OMEROmeros Corp | 1.2 bn | 9.9 | — | — | −34.0% | +76% / +679% |
| IRWDIronwood Pharmaceuticals Inc | 667.2 m | 4.5 | — | 37.4% | −15.7% | +15% / −59% |
| RCKTRocket Pharmaceuticals, Inc. | 267.3 m | — | -4.8% | — | unavailable | −29% / −90% |
1- and 3-year price returns: for ZLAB from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 06 Aug 2026; since then the company filed 8-K (05 Nov 2026 · results), 10-Q (05 Nov 2026).
In brief
Zai Lab is a biopharmaceutical company with a substantial presence in Greater China and the United States, commercializing products in oncology, immunology, neuroscience and infectious disease while developing its own candidates, including zoci. The company reported total revenue of 460.2 million USD in fiscal 2025, and 106.3 million USD in the second quarter of 2026 as it shifts toward a more developed internal portfolio 123.
SWOT
Strengths
- The company has a diversified commercial portfolio across several therapeutic areas and a solid operating presence in China 1.
- There is a growing internal pipeline with candidates in clinical phases and important regulatory designations 23.
- The company has partnerships with several global companies, which may give it access to clinical and commercial expertise 1.
Weaknesses
- The company has reported net losses continuously and expects losses to continue for at least the next few quarters 1.
- Sales of some key products have recently fallen due to price adjustments and shifts in hospital utilisation 2.
- Operations are concentrated largely in mainland China, making the company dependent on a single regulatory environment 1.
Opportunities
- If zoci advances through phase 3 studies and gains approvals, the company could significantly expand its global market 3.
- The launch of KarXT and its potential NRDL inclusion could open a new revenue source if patient access improves 2.
- Rising revenue from XACDURO and NUZYRA suggests hospital adoption could support future growth 12.
Threats
- Trade tensions and restrictions between the US and China could affect access to capital and the value of the company's shares 1.
- Competition and volume-based procurement for generics could reduce prices and volumes for existing products 12.
- Clinical trial failures or regulatory delays could postpone planned launches and revenue growth 13.
Risks
- Continuing losseshigh
The company has reported losses and expects them to continue, which could affect its ability to fund the pipeline without new capital sources 1.
- Geopolitical riskhigh
Changes in US-China relations can affect operations, the market and access to funding, which the company considers a significant risk 1.
- Regulatory risk in Chinahigh
The Chinese legal system and government policies can change or be interpreted differently, which could affect the company's business 1.
- Reliance on third partiesmedium
The company depends on external licensors and suppliers for manufacturing and clinical studies, and their problems could delay supply or approvals 1.
- Pricing and procurement pressuremedium
Price adjustments in NRDL negotiations and competition in volume-based procurement can reduce revenue from existing products 12.
Investment thesis
What would need to be true (bull case)
- If revenue from existing products recovers and the internal pipeline meets its goals, the company could convert its progress into stronger growth in the coming years 23.
- FDA and EMA designations for zoci suggest regulatory interest in the company's international programme 2.
- Diversifying the commercial portfolio across several therapeutic areas may reduce reliance on any single product 1.
What would break the thesis
- If losses continue and funding becomes more costly, the company could be forced to limit investment in its pipeline 1.
- Geopolitical and regulatory risks in China could limit access to capital or to international markets 1.
- If ZEJULA and other products do not recover sales, the growth the company expects for 2027 could be delayed 23.
What to watch
- Results of the DLLEVATE phase 3 study for zoci2027
- FDA decision on povetacicept in IgANNovember 2026
- NRDL inclusion of KarXT and VYVGART Hytrulo2027
- Trend in commercial revenue and net losses in upcoming quartersQ3 2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 06 Aug 2026; since then the company filed 8-K (05 Nov 2026 · results), 10-Q (05 Nov 2026).
The business
Zai Lab describes its business as a commercial-stage biopharmaceutical company focused on discovering, developing and commercializing products for conditions with significant unmet medical needs 1. At the end of 2025 it had seven commercial programs with approved products launched in one or more Greater China territories, rising to eight by the second quarter of 2026 with the launch of KarXT in mainland China 12. The company combines in-licensed partnerships with an internal pipeline including global candidates such as zoci and ZL-1503 13.
Segments
Commercial products in Greater China
The commercial portfolio includes ZEJULA, VYVGART / VYVGART Hytrulo, NUZYRA, OPTUNE, QINLOCK, XACDURO and AUGTYRO, with KarXT added in 2026 12. ZEJULA remains the largest product by revenue but has been affected by new volume-based procurement dynamics for generic olaparib 12.
Partnerships and licences
Many products are licensed from global partners, and milestone and royalty payment obligations could become significant if programs advance 1.
Market context
The company operates mainly in mainland China, where it sells through hospitals and the National Reimbursement Drug List (NRDL), with product revenue reported net of returns and distributor rebates 1. The company describes the oncology market in China as having a very large number of annual new cases, which supports potential demand for its products 1.
The Chinese regulatory and commercial environment and US-China relations are key factors for Zai Lab's outlook, and the company explicitly identifies them as risks 1.
Trends
- Competitive pressure in the PARPi classheadwind
Competition within the PARP inhibitor class in China has intensified, and volume-based procurement for generics can reduce ZEJULA sales 12.
- Wider access through NRDL and insurancetailwind
NRDL listing and supplemental insurance are levers the company uses to extend access to its products, and it is preparing NRDL applications for KarXT and VYVGART Hytrulo in 2027 123.
- US-China geopolitical tensionsheadwind
Trade restrictions, data controls and other policies affecting US-China relations could influence operations, access to capital and the value of the company's securities 1.
- Maturing internal pipelinemixed
Progress for zoci and ZL-1503, including FDA and EMA designations, could support the company's shift from licensing products toward developing its own 23.
Competitive position
- Other PARP inhibitors in China
Products in the same therapeutic class, including generic olaparib, compete with ZEJULA in the Chinese market 12.
- Developers of anti-DLL3 ADCs
Companies developing similar therapies for small cell lung cancer compete with the zoci programme 3.
- Other myasthenia gravis treatments
Other therapies for myasthenia gravis compete with VYVGART in the treatment market 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report05 Nov 2026
- Current report05 Nov 2026Results of operations · Financial statements and exhibits
- Current report23 Oct 2026Material agreement · Item 3.02 · Regulation FD disclosure · Other events · Financial statements and exhibits
- Quarterly report06 Aug 2026
- Current report06 Aug 2026Results of operations · Financial statements and exhibits
- Current report17 Jun 2026Shareholder vote
- Current report21 May 2026Departure or appointment of officers
- Quarterly report07 May 2026
- Current report07 May 2026Results of operations · Financial statements and exhibits
- Proxy statement28 Apr 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Zai Lab Limited · 26 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Zai Lab Limited · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Zai Lab Limited · 06 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.